Table 5.
18-Month TTNT Rates (N = 200) | 18-Month OS Rates (N = 200) |
|
---|---|---|
Total [%] (95% CI) | 64.5 (57.3–72.6) | 88.1 (82.7–93.8) |
Age | ||
<70 years | 65.6 (56.9–75.7) | 90.6 (84.8–96.9) |
≥70 years | 62.0 (50.1–76.7) | 82.3 (71.5–94.8) |
Gender | ||
Female | 63.5 (52.4–77.0) | 90.4 (83.2–98.3) |
Male | 65.1 (56.1–75.6) | 86.5 (79.1–94.5) |
BRAF status | ||
BRAF negative | 54.9 (44.0–68.6) | 81.0 (70.7–92.9) |
BRAF positive | 66.2 (56.2–78.0) | 91.4 (85.3–97.8) |
AJCC stage (8th edition) | ||
Stage IIIA | 80.7 (62.5–100) | 100 (100–100) |
Stage IIIB | 72.1 (59.7–87.1) | 91.2 (82.1–100) |
Stage IIIC | 57.7 (48.3–68.8) | 85.5 (78.2–93.4) |
Stage IIID * | 83.3 (58.3–100) * | 83.3 (58.3–100) * |
Time on next treatment (TTNT) and overall survival (OS) at 18 months. N: number of patients included in the analysis, AJCC: American Joint Committee on Cancer; BRAF: BRAF mutation status. * Estimates are uncertain due to the small number of patients (n = 7).